Document is current
Any future updates will be listed below
-
Authors
Lems, W. F. https://orcid.org/0000-0002-6885-3953
Paccou, J.
Zhang, J.
Fuggle, N. R.
Chandran, M.
Harvey, N. C.
Cooper, C.
Javaid, K.
Ferrari, S.
Akesson, K. E.
,
Akesson, K.E.
Brandi, M.L.
Chandran, M.
Chevalley, T.
Cooper, C.
Fardellone, P.
Goemaere, S.
Harvey, N.C.
Holzer, G.
Javaid, M.K.
Lems, W.
Lewiecki, E.M.
Lyritis, G.
Napoli, N.
Paccou, J.
Silverman, S.
Sosa, M.
Thomas, T.
- License Information
-
More Information
Article History
Received: 21 October 2020
Accepted: 16 December 2020
First Online: 21 January 2021
Compliance with ethical standards
:
: WFL: received fees for lectures and advisory boards from Amgen, Eli Lilly, UCB, Pfizer, Galapagos and Curaphar; JZ: no conflict of interest; NRF: no conflict of interest; NCH: reports consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma. CC: received lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Kyowa Kirin, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB. MKJ: received fees for lectures and advisory boards from Amgen, UCB, KLA: Amgen, Astellas, Chugai, Renapharma, UCB.
